Immunome (NASDAQ:IMNM) Releases Earnings Results, Misses Expectations By $0.27 EPS

Immunome (NASDAQ:IMNMGet Rating) posted its earnings results on Thursday. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.27), Fidelity Earnings reports.

Shares of NASDAQ IMNM traded down $0.30 during trading hours on Friday, hitting $2.24. 35,558 shares of the stock were exchanged, compared to its average volume of 115,144. The company’s fifty day simple moving average is $4.38 and its two-hundred day simple moving average is $10.13. The company has a market cap of $27.17 million, a PE ratio of -0.82 and a beta of 0.03. Immunome has a 1-year low of $2.09 and a 1-year high of $27.80.

IMNM has been the subject of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunome in a research note on Monday, May 9th. Chardan Capital dropped their price objective on shares of Immunome from $16.00 to $9.00 in a research note on Friday. Finally, Zacks Investment Research upgraded shares of Immunome from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Friday.

A number of institutional investors and hedge funds have recently made changes to their positions in IMNM. Renaissance Technologies LLC bought a new stake in Immunome during the first quarter worth $80,000. Bank of America Corp DE acquired a new stake in shares of Immunome in the 4th quarter valued at $81,000. Marshall Wace LLP boosted its holdings in shares of Immunome by 27.6% in the 4th quarter. Marshall Wace LLP now owns 10,654 shares of the company’s stock valued at $138,000 after purchasing an additional 2,306 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Immunome by 9,375.8% in the 2nd quarter. Morgan Stanley now owns 11,371 shares of the company’s stock valued at $196,000 after purchasing an additional 11,251 shares in the last quarter. Finally, State Street Corp boosted its holdings in shares of Immunome by 112.6% in the 4th quarter. State Street Corp now owns 27,000 shares of the company’s stock valued at $350,000 after purchasing an additional 14,300 shares in the last quarter. Institutional investors and hedge funds own 23.97% of the company’s stock.

About Immunome (Get Rating)

Immunome, Inc, a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19.

Recommended Stories

Earnings History for Immunome (NASDAQ:IMNM)

Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.